vs

Side-by-side financial comparison of CLOVER HEALTH INVESTMENTS, CORP. (CLOV) and Weatherford International plc (WFRD). Click either name above to swap in a different company.

Weatherford International plc is the larger business by last-quarter revenue ($1.2B vs $749.2M, roughly 1.5× CLOVER HEALTH INVESTMENTS, CORP.). Weatherford International plc runs the higher net margin — 9.5% vs 3.6%, a 5.8% gap on every dollar of revenue. On growth, CLOVER HEALTH INVESTMENTS, CORP. posted the faster year-over-year revenue change (62.0% vs -8.3%). Over the past eight quarters, CLOVER HEALTH INVESTMENTS, CORP.'s revenue compounded faster (45.0% CAGR vs -9.5%).

Clover Health Investments, Corp. is an American health care company founded in 2014. The company provides Medicare Advantage (MA) insurance plans and operates as a direct contracting entity with the U.S. government. The company manages care for Medicare beneficiaries in 11 states and started trading publicly on January 8, 2021.

Weatherford International plc is an American multinational oilfield service company, headquartered in the US and operating in 75 countries globally across the oil and natural gas producing regions. The company provides technical equipment and services used for drilling, evaluation, completion, production, and intervention on gas and oil wells.

CLOV vs WFRD — Head-to-Head

Bigger by revenue
WFRD
WFRD
1.5× larger
WFRD
$1.2B
$749.2M
CLOV
Growing faster (revenue YoY)
CLOV
CLOV
+70.3% gap
CLOV
62.0%
-8.3%
WFRD
Higher net margin
WFRD
WFRD
5.8% more per $
WFRD
9.5%
3.6%
CLOV
Faster 2-yr revenue CAGR
CLOV
CLOV
Annualised
CLOV
45.0%
-9.5%
WFRD

Income Statement — Q1 FY2026 vs Q1 FY2026

Metric
CLOV
CLOV
WFRD
WFRD
Revenue
$749.2M
$1.2B
Net Profit
$27.3M
$109.0M
Gross Margin
Operating Margin
3.6%
10.7%
Net Margin
3.6%
9.5%
Revenue YoY
62.0%
-8.3%
Net Profit YoY
42.1%
EPS (diluted)
$0.05
$1.49

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CLOV
CLOV
WFRD
WFRD
Q1 26
$749.2M
$1.2B
Q4 25
$487.7M
$1.3B
Q3 25
$496.6M
$1.2B
Q2 25
$477.6M
$1.2B
Q1 25
$462.3M
$1.2B
Q4 24
$337.0M
$1.3B
Q3 24
$331.0M
$1.4B
Q2 24
$356.3M
$1.4B
Net Profit
CLOV
CLOV
WFRD
WFRD
Q1 26
$27.3M
$109.0M
Q4 25
$-49.3M
$138.0M
Q3 25
$-24.4M
$81.0M
Q2 25
$-10.6M
$136.0M
Q1 25
$-1.3M
$76.0M
Q4 24
$-22.1M
$112.0M
Q3 24
$-9.2M
$157.0M
Q2 24
$7.4M
$125.0M
Gross Margin
CLOV
CLOV
WFRD
WFRD
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
24.5%
Q2 24
30.3%
Operating Margin
CLOV
CLOV
WFRD
WFRD
Q1 26
3.6%
10.7%
Q4 25
-10.1%
15.4%
Q3 25
-4.9%
14.4%
Q2 25
-2.2%
19.7%
Q1 25
-0.3%
11.9%
Q4 24
-6.4%
14.8%
Q3 24
-2.7%
17.2%
Q2 24
2.0%
18.8%
Net Margin
CLOV
CLOV
WFRD
WFRD
Q1 26
3.6%
9.5%
Q4 25
-10.1%
10.7%
Q3 25
-4.9%
6.6%
Q2 25
-2.2%
11.3%
Q1 25
-0.3%
6.4%
Q4 24
-6.6%
8.4%
Q3 24
-2.8%
11.1%
Q2 24
2.1%
8.9%
EPS (diluted)
CLOV
CLOV
WFRD
WFRD
Q1 26
$0.05
$1.49
Q4 25
$1.91
Q3 25
$1.12
Q2 25
$1.87
Q1 25
$1.03
Q4 24
$1.53
Q3 24
$2.06
Q2 24
$1.66

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CLOV
CLOV
WFRD
WFRD
Cash + ST InvestmentsLiquidity on hand
$177.6M
$1.0B
Total DebtLower is stronger
$1.5B
Stockholders' EquityBook value
$339.4M
$1.8B
Total Assets
$697.7M
Debt / EquityLower = less leverage
0.84×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CLOV
CLOV
WFRD
WFRD
Q1 26
$177.6M
$1.0B
Q4 25
$78.3M
$987.0M
Q3 25
$967.0M
Q2 25
$943.0M
Q1 25
$873.0M
Q4 24
$194.5M
$916.0M
Q3 24
$288.0M
$920.0M
Q2 24
$254.8M
$862.0M
Total Debt
CLOV
CLOV
WFRD
WFRD
Q1 26
$1.5B
Q4 25
$1.5B
Q3 25
$1.5B
Q2 25
$1.6B
Q1 25
$1.6B
Q4 24
$1.6B
Q3 24
$1.6B
Q2 24
$1.6B
Stockholders' Equity
CLOV
CLOV
WFRD
WFRD
Q1 26
$339.4M
$1.8B
Q4 25
$308.7M
$1.7B
Q3 25
$340.9M
$1.6B
Q2 25
$344.2M
$1.5B
Q1 25
$336.1M
$1.4B
Q4 24
$341.1M
$1.3B
Q3 24
$342.2M
$1.3B
Q2 24
$324.9M
$1.2B
Total Assets
CLOV
CLOV
WFRD
WFRD
Q1 26
$697.7M
Q4 25
$541.0M
$5.2B
Q3 25
$559.7M
$5.3B
Q2 25
$575.0M
$5.1B
Q1 25
$583.7M
$5.1B
Q4 24
$580.7M
$5.2B
Q3 24
$653.0M
$5.2B
Q2 24
$674.2M
$5.1B
Debt / Equity
CLOV
CLOV
WFRD
WFRD
Q1 26
0.84×
Q4 25
0.86×
Q3 25
0.94×
Q2 25
1.04×
Q1 25
1.17×
Q4 24
1.26×
Q3 24
1.21×
Q2 24
1.33×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CLOV
CLOV
WFRD
WFRD
Operating Cash FlowLast quarter
$136.0M
Free Cash FlowOCF − Capex
$85.0M
FCF MarginFCF / Revenue
7.4%
Capex IntensityCapex / Revenue
4.7%
Cash ConversionOCF / Net Profit
1.25×
TTM Free Cash FlowTrailing 4 quarters
$470.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CLOV
CLOV
WFRD
WFRD
Q1 26
$136.0M
Q4 25
$-66.9M
$268.0M
Q3 25
$12.1M
$138.0M
Q2 25
$5.4M
$128.0M
Q1 25
$-16.3M
$142.0M
Q4 24
$34.8M
$249.0M
Q3 24
$50.0M
$262.0M
Q2 24
$44.8M
$150.0M
Free Cash Flow
CLOV
CLOV
WFRD
WFRD
Q1 26
$85.0M
Q4 25
$-69.0M
$217.0M
Q3 25
$11.4M
$94.0M
Q2 25
$4.8M
$74.0M
Q1 25
$-16.5M
$65.0M
Q4 24
$33.3M
$149.0M
Q3 24
$49.6M
$184.0M
Q2 24
$44.4M
$88.0M
FCF Margin
CLOV
CLOV
WFRD
WFRD
Q1 26
7.4%
Q4 25
-14.1%
16.8%
Q3 25
2.3%
7.6%
Q2 25
1.0%
6.1%
Q1 25
-3.6%
5.4%
Q4 24
9.9%
11.1%
Q3 24
15.0%
13.1%
Q2 24
12.5%
6.3%
Capex Intensity
CLOV
CLOV
WFRD
WFRD
Q1 26
4.7%
Q4 25
0.4%
4.0%
Q3 25
0.1%
3.6%
Q2 25
0.1%
4.5%
Q1 25
0.0%
6.5%
Q4 24
0.5%
7.5%
Q3 24
0.1%
5.5%
Q2 24
0.1%
4.4%
Cash Conversion
CLOV
CLOV
WFRD
WFRD
Q1 26
1.25×
Q4 25
1.94×
Q3 25
1.70×
Q2 25
0.94×
Q1 25
1.87×
Q4 24
2.22×
Q3 24
1.67×
Q2 24
6.04×
1.20×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CLOV
CLOV

Segment breakdown not available.

WFRD
WFRD

Middle East/North Africa/Asia$476.0M41%
Europe/Sub-Sahara Africa/Russia$233.0M20%
Latin America$223.0M19%
North America$220.0M19%

Related Comparisons